The Latest Breaking News from Biogen

Biogen stock jumped Wednesday after the FDA gave its Eisai-partnered Alzheimer's treatment a fast track designation.

Two of Biogen's newest drugs walloped first-quarter sales expectations on Wednesday, and helped Biogen stock jump.

NHS cost threshold has not been raised by National Institute for Health and Care Excellence since 2004

The Alzheimer's treatment space is heating up — and could soon leave Eli Lilly's embattled drug, donanemab, in the dust, experts say.

The S&P 500 Index ($SPX ) (SPY ) Friday closed down -0.65%, the Dow Jones Industrials Index ($DOWI ) (DIA ) closed down -0.18% and the Nasdaq 100 Index ($IUXX ) (QQQ ) closed down -1.53%. Stock indexes on Friday gave up early gains and closed moderately lower. Stocks on...

Eli Lilly's highly anticipated Alzheimer's drug has been held back for further review by regulators, the US pharmaceutical giant said Friday, in a blow for patients with the devastating brain disorder.

Biogen stock jumped Friday after the FDA delayed its approval decision on Eli Lilly's rival Alzheimer's treatment, donanemab.

As biotech stocks swing back into favor on Wall Street, here's a look at five picks that could deliver significant gains, according to analysts.

Despite macroeconomic challenges, the biotech industry thrives on innovation, demand, adaptability, and technological advancements, demonstrating resilience. So, let’s analyze the upside potential of popular biotech stocks Biogen (BIIB) and Moderna (MRNA).

Biogen's turnaround is still a "work in progress," an analyst said Tuesday as Biogen stock slumped on light fourth-quarter profit.

Because of its strategic focus on research and therapy improvements for long-term growth, Biogen (BIIB) could come under heat for the mixed outcomes of its recent acquisitions. As stakeholders anticipate the forthcoming earnings release, let's seek insights into the company's future trajectory and implications for BIIB shares. Read on….